GlucoTrack (NASDAQ:GCTK) Shares to Reverse Split on Monday, August 31st

GlucoTrack, Inc. (NASDAQ:GCTK) shares are scheduled to reverse split before the market opens on Monday, August 31st. The 1-15 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, August 30th.

GlucoTrack Price Performance

Shares of GCTK traded down $0.03 during mid-day trading on Thursday, reaching $0.29. The company had a trading volume of 1,670,509 shares, compared to its average volume of 6,231,775. The company has a market capitalization of $2.21 million, a price-to-earnings ratio of -0.03 and a beta of 0.70. The company has a debt-to-equity ratio of 0.08, a quick ratio of 0.46 and a current ratio of 0.46. The company’s 50 day simple moving average is $0.39 and its 200 day simple moving average is $0.75. GlucoTrack has a 1-year low of $0.25 and a 1-year high of $14.14.

GlucoTrack (NASDAQ:GCTK) last announced its quarterly earnings results on Friday, August 14th. The company reported $0.76 earnings per share (EPS) for the quarter.

Analysts Set New Price Targets

GCTK has been the topic of several recent research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of GlucoTrack in a report on Friday, July 17th. Wall Street Zen raised GlucoTrack from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

Hedge Funds Weigh In On GlucoTrack

Hedge funds have recently modified their holdings of the business. Bank of America Corp DE increased its holdings in GlucoTrack by 102,125.0% in the second quarter. Bank of America Corp DE now owns 4,089 shares of the company’s stock valued at $25,000 after purchasing an additional 4,085 shares during the period. Boothbay Fund Management LLC acquired a new position in GlucoTrack during the 4th quarter worth about $52,000. Finally, Ikarian Capital LLC acquired a new position in GlucoTrack during the 4th quarter worth about $177,000. Institutional investors and hedge funds own 10.92% of the company’s stock.

GlucoTrack Company Profile

GlucoTrack, Inc, a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc and changed its name to GlucoTrack, Inc in November 2021. GlucoTrack, Inc was founded in 2001 and is based in Rutherford, New Jersey.